Cargando…

Current Challenges in the Management of Prolactinomas

Although the diagnosis of prolactinoma is often straightforward and the treatment strategy has been well defined in recent guidelines, several challenging issues persist in their management. The differential diagnosis of a large pituitary tumour with moderately elevated prolactin (PRL) concentration...

Descripción completa

Detalles Bibliográficos
Autor principal: Maiter, Dominique
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Touch Medical Media 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5819061/
https://www.ncbi.nlm.nih.gov/pubmed/29632566
http://dx.doi.org/10.17925/EE.2015.11.01.39
_version_ 1783301131011620864
author Maiter, Dominique
author_facet Maiter, Dominique
author_sort Maiter, Dominique
collection PubMed
description Although the diagnosis of prolactinoma is often straightforward and the treatment strategy has been well defined in recent guidelines, several challenging issues persist in their management. The differential diagnosis of a large pituitary tumour with moderately elevated prolactin (PRL) concentrations is sometimes difficult, and prolonged treatment with a dopamine agonist may be inappropriate when the diagnosis of a prolactinoma is not sufficiently well substantiated. Also, timely withdrawal of dopamine agonist treatment and the remaining indications of transsphenoidal surgery are still matters of debate. Last but not least, the management of resistant or aggressive prolactinomas remains a challenge for the clinician, especially when they occur in young patients.
format Online
Article
Text
id pubmed-5819061
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Touch Medical Media
record_format MEDLINE/PubMed
spelling pubmed-58190612018-04-09 Current Challenges in the Management of Prolactinomas Maiter, Dominique Eur Endocrinol Pituitary Disorders Editorial Although the diagnosis of prolactinoma is often straightforward and the treatment strategy has been well defined in recent guidelines, several challenging issues persist in their management. The differential diagnosis of a large pituitary tumour with moderately elevated prolactin (PRL) concentrations is sometimes difficult, and prolonged treatment with a dopamine agonist may be inappropriate when the diagnosis of a prolactinoma is not sufficiently well substantiated. Also, timely withdrawal of dopamine agonist treatment and the remaining indications of transsphenoidal surgery are still matters of debate. Last but not least, the management of resistant or aggressive prolactinomas remains a challenge for the clinician, especially when they occur in young patients. Touch Medical Media 2015-04 2015-04-11 /pmc/articles/PMC5819061/ /pubmed/29632566 http://dx.doi.org/10.17925/EE.2015.11.01.39 Text en © The Author(s) 2015 http://creativecommons.org/licenses/by/2.5/ This article is published under the Creative Commons Attribution Noncommercial License, which permits any non-commercial use, distribution, adaptation and reproduction provided the original author(s) and source are given appropriate credit.
spellingShingle Pituitary Disorders Editorial
Maiter, Dominique
Current Challenges in the Management of Prolactinomas
title Current Challenges in the Management of Prolactinomas
title_full Current Challenges in the Management of Prolactinomas
title_fullStr Current Challenges in the Management of Prolactinomas
title_full_unstemmed Current Challenges in the Management of Prolactinomas
title_short Current Challenges in the Management of Prolactinomas
title_sort current challenges in the management of prolactinomas
topic Pituitary Disorders Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5819061/
https://www.ncbi.nlm.nih.gov/pubmed/29632566
http://dx.doi.org/10.17925/EE.2015.11.01.39
work_keys_str_mv AT maiterdominique currentchallengesinthemanagementofprolactinomas